For the quarter ending 2025-09-30, IGC made $191K in revenue. -$1,840K in net income. Net profit margin of -963.35%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 191 | 328 | 330 | 257 |
| Cost of revenue | 92 | 174 | 176 | 153 |
| Selling, general, and administrative expenses | 1,410 | 1,208 | 569 | 1,130 |
| Research and development expenses | 1,588 | 851 | 997 | 852 |
| Operating loss | -2,899 | -1,905 | -1,412 | -1,878 |
| Other income, net | 1,078 | 306 | 215 | 49 |
| Loss before income taxes | -1,821 | -1,599 | -1,197 | -1,829 |
| Income tax expense | 0 | 0 | - | - |
| Net loss attributable to common stockholders | -1,821 | -1,599 | -1,197 | -1,829 |
| Foreign currency translation adjustments | -19 | -3 | 6 | -18 |
| Comprehensive loss | -1,840 | -1,602 | -1,191 | -1,847 |
| Basic and diluted (in dollars per share) | -0.02 | -0.02 | -0.025 | -0.02 |
| Basic and diluted (in dollars per share) | -0.02 | -0.02 | -0.025 | -0.02 |
| Weighted-average number of shares used in computing loss per share amounts (in shares) | 90,457,910 | 83,027,117 | -149,936,496 | 77,633,004 |
| Weighted-average number of shares used in computing loss per share amounts (in shares) | 90,457,910 | 83,027,117 | -38,561,479 | 77,633,004 |
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)